Venom-Derived Peptide Drugs: From Snake Bite to Pharmacy

Drug discovery

Venom-derived peptide drugs are approved medicines whose starting point was a molecule an animal evolved to disable another animal. A pit viper, a Gila monster, a cone snail, a leech and a pygmy rattlesnake have each contributed the chemistry behind a drug you can find in a US hospital pharmacy today.

Venom is an unusually good place to go shopping for drug leads, and the reason is selectivity. Venom components are under intense evolutionary pressure to hit one target hard and fast without wasting energy on anything else. As one 2024 review puts it, venom toxins are mostly highly structured peptides held together by disulfide bridges, which gives them the conformation to bind a receptor tightly and confers stability and resistance to proteases. That is a description of a good drug lead. The awkward part comes later.

The venom-derived peptide drugs that reached the market

A 2020 review in Frontiers in Pharmacology counts eleven approved toxin-based molecules on the market worldwide: one from cone snails, two from lizards, two from leeches and six from snakes. Not all eleven are FDA-approved, and not all of them are peptides. The distinction matters more than it sounds.

Captopril: the one everyone gets wrong

Captopril is routinely described as a snake-venom drug. It is not a venom peptide. Brazilian pit viper (Bothrops jararaca) venom contains bradykinin-potentiating peptides that block angiotensin-converting enzyme, and one of them, teprotide, proved in humans that specific ACE inhibition could lower blood pressure — but teprotide could only be given by injection. Captopril was designed by miniaturising the peptide down to a small molecule and adding a succinyl group to a proline residue, which is what made oral administration possible. It reached the market in 1981 as the first animal-toxin-based drug approved for human use. Enalapril traces to the same chemistry, and tirofiban is a comparable case: a non-peptide RGD mimetic based on echistatin from the saw-scaled viper.

Exenatide: the Gila monster and the GLP-1 era

In 1992, Eng and colleagues isolated exendin-4, a 39-amino-acid peptide, from the venom of Heloderma suspectum, the Gila monster. It differs from the closely related exendin-3 at two positions and, critically, its N-terminus resists the peptidases that rapidly clear endogenous GLP-1 — making it more potent and longer-lasting at the same receptor. Synthetic exendin-4 became exenatide, approved by the FDA on 28 April 2005 as Byetta, the first GLP-1 analogue. Lixisenatide, approved 27 July 2016, is built from the first 39 residues of exendin-4 with a proline deletion and six added lysines.

It is worth pausing on that lineage. The entire modern GLP-1 drug class descends, conceptually, from a lizard that lives in the Sonoran Desert.

Ziconotide: the cone snail, and the price of being a peptide

The Prialt label describes ziconotide as a synthetic equivalent of a naturally occurring conopeptide from the piscivorous marine snail Conus magus: a 25-amino-acid polybasic peptide with three disulfide bridges and a molecular weight of 2,639 daltons. It is an N-type calcium channel antagonist that binds channels on primary nociceptive afferents in the superficial dorsal horn. Initial US approval was 2004.

It is also the clearest illustration of what being a peptide costs. Prialt is not for intravenous administration; it is delivered intrathecally by an implanted or external microinfusion pump, at a maximum recommended 19.2 mcg per day, and it carries a boxed warning for severe neuropsychiatric adverse reactions. The label explains why the route is so restrictive: ziconotide is expected to be completely degraded by endopeptidases and exopeptidases located throughout the body.

Bivalirudin, desirudin and the medicinal leech

Hirudin, a 65-amino-acid anticoagulant with three disulfide bridges, comes from the salivary glands of Hirudo medicinalis. Two descendants reached the US market. Bivalirudin (Angiomax, initial US approval 2000) is a synthetic 20-amino-acid peptide of 2,180 daltons that inhibits thrombin reversibly at both the catalytic site and the anion-binding exosite; it grew out of the “hirulog” bivalent inhibitor design work published in 1990. Desirudin (Iprivask, FDA approval letter dated 4 April 2003) takes the other approach — it is recombinant hirudin expressed in Saccharomyces cerevisiae, differing from the natural molecule only by the absence of a sulfate group on Tyr-63, with a thrombin inhibition constant around 2.6 × 10⁻¹³ M.

Eptifibatide: one amino acid of difference

The barbourin story is the best single argument for screening venoms at all. Scarborough and colleagues screened 62 snake venoms in 1991. Fifty-two of them inhibited platelet GPIIb-IIIa — inhibition, it turns out, is easy to find. Only one venom, from Sistrurus miliarius barbouri, the southeastern pygmy rattlesnake, was specific for GPIIb-IIIa versus other integrins. The reason was structural: barbourin was the first viper-venom GPIIb-IIIa antagonist lacking the usual RGD motif, carrying KGD instead, and the conservative lysine-for-arginine substitution appeared to be the sole feature imparting that specificity. Eptifibatide, a cyclic heptapeptide built on that insight, was approved 18 May 1998.

Why almost none of them can be swallowed

Every FDA-approved venom-peptide drug above is parenteral: intravenous for eptifibatide and bivalirudin, subcutaneous for exenatide, lixisenatide and desirudin, intrathecal for ziconotide. The two that reach ordinary oral or small-molecule dosing — captopril and tirofiban — are precisely the two that stopped being peptides. This is the general rule for the class, and it is the same reason peptides are not usually pills.

Medicinal chemists have several ways to push back on that constraint: cyclisation, which is exactly what eptifibatide uses to resist proteolysis, D-amino acid substitution, and half-life extension strategies such as lipidation and albumin binding. None of them turns an intrathecal conopeptide into a tablet. Understanding how peptides are degraded and their pharmacokinetics explains why.

What the venom cabinet still has in it

Two more venom-derived agents are approved outside the United States: batroxobin, a thrombin-like serine protease of about 33 kDa purified from Bothrops atrox and Bothrops moojeni venom that cleaves the fibrinogen alpha chain, and cobratide, an alpha-neurotoxin from Naja naja atra approved in China in 1998. Neither has FDA approval, which is a useful reminder that “approved” is a jurisdictional statement, not a global one. Chlorotoxin, a 36-amino-acid, 4,070-dalton scorpion peptide with four disulfide bonds, remains one of the most-studied investigational venom peptides.

What has not changed since 1981 is the underlying trade. Venom hands you extraordinary target selectivity and a molecule that is stable in the very narrow sense of resisting proteases in a prey animal. It does not hand you oral bioavailability, tissue distribution, or a comfortable safety margin. Whether the answer is to keep the peptide and accept an infusion pump, or to redesign it into something that is no longer a peptide at all, has been the recurring decision for four decades.

Frequently asked questions

Is captopril a venom peptide?

No. Captopril is a small-molecule ACE inhibitor designed from bradykinin-potentiating peptides in Bothrops jararaca venom. The 2020 Frontiers in Pharmacology review states it was designed by miniaturising the original molecule and adding a succinyl group to a proline residue, which allowed oral administration, because the native venom peptide was impossible to give orally. It was approved in 1981.

Why must ziconotide be given into the spinal fluid?

Because it is a 25-amino-acid peptide that its FDA label says is expected to be completely degraded by endopeptidases and exopeptidases distributed throughout the body. The Prialt label states plainly that it is not for intravenous administration; it is infused intrathecally by pump, and carries a boxed warning for severe neuropsychiatric reactions.

Which animals have produced approved medicines?

By the 2020 review's tally of eleven approved toxin-based molecules worldwide: cone snails (ziconotide), lizards (exenatide, lixisenatide), medicinal leeches (bivalirudin, desirudin) and snakes (captopril, enalapril, tirofiban, eptifibatide, batroxobin, cobratide). Batroxobin and cobratide are approved in China rather than by the FDA.

Why are venom peptides such good drug leads?

Selectivity. Venom toxins are highly structured, disulfide-bridged peptides shaped to bind one receptor precisely, which also gives them stability against proteases. The barbourin screen makes the point concretely: of 62 snake venoms tested, 52 inhibited platelet GPIIb-IIIa, but only one was specific for it.

Informational only — not medical advice · 21+. VialHelp does not sell peptides and does not recommend any product or vendor. Consult a qualified healthcare professional for anything health-related.